Clinical Trials Logo
  1. Home
  2. Hypoparathyroidism
  3. NCT03728959
  4. Details
NCT03728959 Clinical Trial

Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism.

Hypoparathyroidism Clinical Trial

— KS-4-HypoPT  

Official title:
Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism (KS-4-HypoPT).

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03728959
Other study ID # KS-4-HypoPT
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 12, 2018
Est. completion date April 12, 2019

Study information
Verified date December 2019
Source University of Copenhagen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hypoparathyroidism (hypoPT) is characterized by low levels of PTH.

In this study we will test the effects of a liquid meal on the bone remodeling in participants with hypoparathyroidism. Furthermore, we will test the effects of the gut hormones GIP and GLP-2.

Recruitment information / eligibility
Status Completed
Enrollment 7
Est. completion date April 12, 2019
Est. primary completion date April 12, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 76 Years
Eligibility Inclusion Criteria:

- Age between 18 and 76

- Hypoparathyroidism

Exclusion Criteria:

- Diabetes

- Disease in the gastrointestinal tract

- Antiosteoporotic drug

- Long term steroid treatment (within the last 12 months)

- Pregnancy

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Liquid meal (Nutridrink)
Liquid meal ingested over 1 minute.
• GIP
Subcutaneous injected GIP
• GLP-2
Subcutaneous injected GLP-2
• Placebo (saline)
Subcutaneous injected Placebo (saline)

Locations
Country Name City State
Denmark Hvidovre University Hospital Hvidovre

Sponsors (2)
Lead Sponsor Collaborator
University of Copenhagen Hvidovre University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome
Type Measure Description Time frame Safety issue
Other Blood pressure Blood pressure (systolic and diastolic) measured before blood sampling -10 to 240 minutes
Other Heart rate Heart rate measured before blood sampling -10 to 240 minutes
Primary Serum concentration of C-terminal telopeptide (CTX) Marker of bone resorption, measured in serum -10 to 240 minutes
Primary N-terminal propeptide of type 1 procollagen (P1NP) Marker of bone formation, concentration measured in serum -10 to 240 minutes
Secondary PTH PTH concentration measured in serum -10 to 240 minutes
Secondary Glucose-dependent insulinotropic polypeptide (GIP) Gut hormone, concentration measured in plasma -10 to 240 minutes
Secondary Glucagon-like peptide-2 (GLP-2) Gut hormone, concentration measured in plasma -10 to 240 minutes
Secondary Glucagon-like peptide-1 (GLP-1) Gut hormone, concentration measured in plasma -10 to 240 minutes
Secondary Glucose Glucose concentration measured in serum -10 to 240 minutes
Secondary Insulin Insulin concentration measured in serum -10 to 240 minutes
Secondary C-peptide C-peptide concentration measured in serum -10 to 240 minutes
See also
  Status Clinical Trial Phase
Terminated NCT03364738 - Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism Phase 3
Active, not recruiting NCT00856401 - ADD-ON Study to Existing Hypoparathyroidism Studies Phase 3
Completed NCT05043584 - Near-infrared Autofluorescence (NIRAF)-Guided Total Thyroidectomy: Impact in Low-volume, Non-parathyroid Institutions N/A
Recruiting NCT05556629 - A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using NATPARA
Terminated NCT00395538 - Effects of PTH Replacement on Bone in Hypoparathyroidism Phase 3
Completed NCT02910466 - A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism Phase 4
Completed NCT00001304 - Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34 Phase 2
Completed NCT04569604 - QoL and Cognitive Function in Patients With Hypoparathyroidism
Completed NCT03747029 - Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
Completed NCT05684029 - Near-Infrared Autofluorescence With PTH Test Strip as an SOP of Parathyroid in Thyroid Surgery
Completed NCT00473265 - Bone Properties in Hypoparathyroidism: Effects of PTH Phase 2/Phase 3
Active, not recruiting NCT05328076 - Parathyroid Vascularization During Total Thyroidectomy Using Indocyanine Green Angiography
Completed NCT03150108 - Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects Phase 1
Completed NCT04059380 - Evaluation of iMmune Function in Post-surgical and AuToimmune HYpoparathyroidism (EMPATHY)
Active, not recruiting NCT05965167 - Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo Phase 1/Phase 2
Recruiting NCT02986607 - Corticosteroid Rhythms in Hypoparathyroid Patients Early Phase 1
Completed NCT00793689 - Perioperative Parathormone Measurement and Sodium Bicarbonate Infusion Test After Total Thyroidectomy N/A
Completed NCT04671719 - Determination of Circulating Autotaxin in Patients With GNAS or PTH Abnormalities
Completed NCT04750460 - Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). Phase 3
Completed NCT00730210 - Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life Phase 2